[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[S. 2879 Introduced in Senate (IS)]
106th CONGRESS
2d Session
S. 2879
To amend the Public Health Service Act to establish programs and
activities to address diabetes in children and youth, and for other
purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
July 17, 2000
Ms. Collins (for herself, Mr. Breaux, Mr. Abraham, Mr. Bunning, and Mr.
Craig) introduced the following bill; which was read twice and referred
to the Committee on Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To amend the Public Health Service Act to establish programs and
activities to address diabetes in children and youth, and for other
purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Pediatric Diabetes Research and
Prevention Act''.
SEC. 2. PROGRAMS OF CENTERS FOR DISEASE CONTROL AND PREVENTION.
Part B of title III of the Public Health Service Act (42 U.S.C. 243
et seq.) is amended by inserting after section 317G the following
section:
``SEC. 317H. DIABETES IN CHILDREN AND YOUTH.
``(a) National Registry on Juvenile Diabetes.--The Secretary,
acting through the Director of the Centers for Disease Control and
Prevention, shall develop a system to collect data on type 1 diabetes
(or juvenile diabetes), including information with respect to incidence
and prevalence, and shall establish a national registry for such data.
``(b) Advisory Committee on the National Registry on Juvenile
Diabetes.--
``(1) Establishment.--There is established a committee to
be known as the Advisory Committee on the National Registry on
Juvenile Diabetes (referred to in this subsection as the
`committee').
``(2) Membership.--The committee shall be composed of at
least one member, to be appointed by the Secretary, acting
through the Director of the Centers for Disease Control and
Prevention, representing each of the following:
``(A) Epidemiologists with experience in data
registries.
``(B) Patients with type 1 diabetes (or juvenile
diabetes), or family members of the patients.
``(C) Representatives from nonprofit organizations
focused on diabetes research.
``(D) Clinicians who have worked with data
registries.
``(E) Statisticians.
``(F) Ethicists.
``(G) Attorneys.
``(H) Other individuals with an interest in
developing and maintaining the registry described in
subsection (a).
``(3) Period of appointment; vacancies.--Members shall be
appointed for the life of the committee. Any vacancy in the
committee shall not affect the powers of the committee, but
shall be filled in the same manner as the original appointment.
``(4) Duties.--The committee shall study, and make
recommendations to the Secretary regarding, the development and
maintenance of the registry described in subsection (a).
``(5) Powers.--
``(A) Hearings.--The committee may hold such
hearings, sit and act at such times and places, take
such testimony, and receive such evidence as the
committee considers advisable to carry out the
objectives of this section.
``(B) Information from federal agencies.--The
committee may secure directly from any Federal
department or agency such information as the committee
considers necessary to carry out the provisions of this
section. Upon request of the committee, the head of
such department or agency shall furnish such
information to the committee.
``(C) Postal services.--The committee may use the
United States mails in the same manner and under the
same conditions as other departments and agencies of
the Federal Government.
``(6) Personnel.--
``(A) Travel expenses.--The members of the
committee shall not receive compensation for the
performance of services for the committee, but shall be
allowed travel expenses, including per diem in lieu of
subsistence, at rates authorized for employees of
agencies under subchapter I of chapter 57 of title 5,
United States Code, while away from their homes or
regular places of business in the performance of
services for the committee. Notwithstanding section
1342 of title 31, United States Code, the Secretary may
accept the voluntary and uncompensated services of
members of the committee.
``(B) Detail of government employees.--Any Federal
Government employee may be detailed to the committee
without reimbursement, and such detail shall be without
interruption or loss of civil service status or
privilege.
``(7) Permanent committee.--Section 14 of the Federal
Advisory Committee Act (5 U.S.C. App.) shall not apply to the
committee.
``(c) Type 2 Diabetes in Youth.--The Secretary, acting through the
Director of the Centers for Disease Control and Prevention and in
consultation with the Administrator of the Health Resources and
Services Administration, shall implement a national public health
effort to address type 2 diabetes in youth, including--
``(1) enhancing surveillance systems and expanding research
to better assess the prevalence of type 2 diabetes in youth and
determine the extent to which type 2 diabetes is incorrectly
diagnosed as type 1 diabetes (or juvenile diabetes) among
children;
``(2) assisting States in establishing coordinated school
health programs and physical activity and nutrition
demonstration programs to control weight and increase physical
activity among youth; and
``(3) developing and improving laboratory methods to assist
in diagnosis, treatment, and prevention of diabetes including
developing noninvasive ways to monitor blood glucose to prevent
hypoglycema and improving glucometers that measure blood
glucose.
``(d) Authorization of Appropriations.--There are authorized to be
appropriated to carry out this section such sums as may be necessary
for each of fiscal years 2001 through 2005.''.
SEC. 3. PROGRAMS OF NATIONAL INSTITUTES OF HEALTH.
Subpart 3 of part C of title IV of the Public Health Service Act
(42 U.S.C. 285c et seq.) is amended by inserting after section 434 the
following section:
``SEC. 434A. JUVENILE DIABETES.
``(a) Long-Term Epidemiology Studies.--
``(1) In general.--The Director of the Institute shall
conduct or support long-term epidemiology studies in which
individuals with type 1 diabetes (or juvenile diabetes) are
followed for 10 years or more. Such studies shall, in order to
provide a valuable resource for the purposes specified in
paragraph (2), provide for complete characterization of disease
manifestations, description of the appropriate medical history,
elucidation of environmental factors, delineation of
complications, description of results of usual medical
treatment, and acquisition of a variety of other potentially
valuable information and samples (such as samples of blood).
``(2) Purposes.--The purposes referred to in paragraph (1)
with respect to type 1 diabetes (or juvenile diabetes) are the
following:
``(A) Delineation of potential environmental
triggers thought to precipitate or cause type 1
diabetes (or juvenile diabetes).
``(B) Delineation of clinical characteristics or
lab measures associated with complications of the
disease.
``(C) Specification of a potential study population
to enter into clinical trials for prevention and
treatment, as well as genetic studies.
``(b) Clinical Trial Infrastructure and Innovative Treatments for
Juvenile Diabetes.--The Secretary, acting through the Director of the
National Institutes of Health, shall support regional clinical centers
for the cure of type 1 diabetes (or juvenile diabetes) and shall
through such centers provide for--
``(1) a well-characterized population of children
appropriate for clinical trials;
``(2) well-trained clinical scientists able to conduct such
trials;
``(3) appropriate clinical settings able to house such
trials; and
``(4) appropriate statistical capability, data, safety, and
other monitoring capacity.
``(c) Development of Vaccine.--The Secretary, acting through the
appropriate agencies of the Public Health Service, shall provide for a
national effort to develop a vaccine for type 1 diabetes (or juvenile
diabetes). Such effort shall provide for a combination of increased
efforts in research and development of candidate vaccines, coupled with
appropriate ability to conduct large clinical trials in children.
``(d) Authorization of Appropriations.--There are authorized to be
appropriated to carry out this section such sums as may be necessary
for each of fiscal years 2001 through 2005.''.
<all>
Introduced in Senate
Sponsor introductory remarks on measure. (CR S7074-7075)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line